Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors, and risk of hospitalization
Lyu B, Grams ME, Chang A, et al.
Am J Cardiol. 2022;165:124-130.
Leggi
Lyu B, Grams ME, Chang A, et al.
Am J Cardiol. 2022;165:124-130.
Leggi
Ekhlaspour L, Town MA, Raghinaru D, et al.
Diabetes Technol Ther. Pub. online 12 January 2022
Leggi
Uemura F, Okada Y, Mita T, et al.
Diabetes Technol Ther. Pub. online 20 January 2022.
Leggi
Wan SH, Slusser JP, Hodge DO, Chen HH
Am J Cardiol. 2022;165:65-71
Leggi
Kovesdy C , Schmedt N, Folkerts K, et al.
BMC Med. 2022;20(1):2
Leggi
Lithovius R, Antikainen AA, Mutter S, et al.
Diabetes Care. 2022;dc210974
Leggi
Joseph JJ, Deedwania P, Acharya T, et al.
Circulation. 2022;CIR0000000000001040
Leggi
Magliano DJ, Chen L, Carstensen B, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(21):00327-2
Leggi
Kolkailah AA, Wiviott SD, Raz I, et al.
Diabetes Care. 2022;dc211668
Leggi
Chao AM, Wadden TA, Clark JM, et al.
Diabetes Care. 2022;45(1):74-82.
Leggi